• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Demand for EpiPen alternatives jumps as states consider access legislation

March 7, 2017 By Sarah Faulkner

Demand for EpiPen alternatives jumps as states consider access legislationPrescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007.

Generic options for the injector were sparse until Kaleo’s product was re-released in mid-February this year. Mylan launched a generic version of its own device in December last year at half the price of the original and CVS said in January that it will stock Impax Laboratories‘'(NSDQ:IPXL) $10 EpiPen alternative known as Adrenaclick.

Researchers examined more than 60,000 prescriptions for epinephrine auto-injectors between January 2016 and February this year, Athenahealth reported. At the end of last year, EpiPen alternatives comprised just 5.3% of prescriptions for the emergency allergy treatments. By the last week of February, that number grew to nearly 30%.

Some states, including Ohio, New York, Vermont and New Jersey, introduced legislation last week to make it easier for pharmacists to dispense the substitute products.

The newly-introduced bills would allow pharmacists to substitute the pricey EpiPen device for cheaper alternatives without requiring a new prescription written by a physician.

Mylan said in January that it is undergoing an antitrust probe by the Federal Trade Commission into the company’s commercial practices regarding its EpiPen device.

The Canonsburg, Pa.-based company reportedly responded to the allegations that it improperly fought off competition, saying “any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit.”

Mylan has repeatedly challenged rival Teva Pharmaceutical‘s (NYSE:TEVA) efforts to gain regulatory approval for its generic EpiPen device, asserting that Teva’s version is not an exact copy – it has 2 caps, which is not identical to Mylan’s single-cap device. The company argued that because of the design difference, a distressed patient may not be able to quickly use Teva’s version if they were trained to use Mylan’s device.

Last year, the FDA rejected Teva’s application for approval.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Respiratory, Wall Street Beat Tagged With: Impax Laboratories, Kaleo Inc, Mylan, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS